Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERFECT OLE: Inhaled Treprostinil in PH-COPD
NCT03794583Phase 3Terminated
- Sponsor
- United Therapeutics Corporation
- Start
- Dec 2018
- Primary completion
- Nov 2022
- Modality
- Orthosteric Ligands
- Countries
- 3
01
Overview
A Phase 3 trial of treprostinil in pulmonary hypertension (PH), chronic obstructive pulmonary disease (COPD), sponsored by United Therapeutics Corporation. Started Dec 2018; status: terminated.
02
Drugs
treprostinil
03
Conditions
pulmonary hypertension (PH)chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03794583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03794583.